Share Price | Chengdu Olymvax Biopharmaceuticals, Inc. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Net Sales of 25.38%, the company declared Very Positive results in Sep 25

The company has declared positive results for the last 2 consecutive quarters
ROCE(HY) Highest at 6.86%
INTEREST COVERAGE RATIO(Q) Highest at 1,289.5
RAW MATERIAL COST(Y) Fallen by -2.66% (YoY)

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 7,820 Million (Mid Cap)

P/E

173.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.18

Return on Equity

6.56%

Price to Book

8.15

Revenue and Profits:

Net Sales:

197 Million

(Quarterly Results - Dec 2025)

Net Profit:

-25 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

10.49%

6 Months

26.7%

1 Year

83.76%

2 Years

258.39%

3 Years

41.21%

4 Years

59.04%

5 Years

0.0%

Chengdu Olymvax Biopharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

17.39%

EBIT Growth (5y)

-4.86%

EBIT to Interest (avg)

15.30

Debt to EBITDA (avg)

0.61

Net Debt to Equity (avg)

0.18

Sales to Capital Employed (avg)

0.46

Tax Ratio

15.47%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.29%

ROE (avg)

4.40%

Valuation key factors

Factor

Value

P/E Ratio

173

Industry P/E

Price to Book Value

11.18

EV to EBIT

162.83

EV to EBITDA

101.91

EV to Capital Employed

9.46

EV to Sales

15.88

PEG Ratio

0.75

Dividend Yield

ROCE (Latest)

5.81%

ROE (Latest)

6.45%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -2.47% vs 40.61% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -259.49% vs 208.22% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "197.20",
          "val2": "202.20",
          "chgp": "-2.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.20",
          "val2": "24.80",
          "chgp": "-153.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.80",
          "val2": "3.90",
          "chgp": "-2.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.20",
          "val2": "15.80",
          "chgp": "-259.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-124.70%",
          "val2": "77.40%",
          "chgp": "-20.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 19.42% vs 18.83% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 39.49% vs 37.72% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "701.50",
          "val2": "587.40",
          "chgp": "19.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "76.00",
          "val2": "57.40",
          "chgp": "32.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "15.10",
          "val2": "14.50",
          "chgp": "4.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "21.90",
          "val2": "15.70",
          "chgp": "39.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "46.90%",
          "val2": "36.50%",
          "chgp": "1.04%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

197.20

202.20

-2.47%

Operating Profit (PBDIT) excl Other Income

-13.20

24.80

-153.23%

Interest

3.80

3.90

-2.56%

Exceptional Items

0.00

Consolidate Net Profit

-25.20

15.80

-259.49%

Operating Profit Margin (Excl OI)

-124.70%

77.40%

-20.21%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is -2.47% vs 40.61% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -259.49% vs 208.22% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

701.50

587.40

19.42%

Operating Profit (PBDIT) excl Other Income

76.00

57.40

32.40%

Interest

15.10

14.50

4.14%

Exceptional Items

0.00

Consolidate Net Profit

21.90

15.70

39.49%

Operating Profit Margin (Excl OI)

46.90%

36.50%

1.04%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 19.42% vs 18.83% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 39.49% vs 37.72% in Dec 2024

All Annual Results

Company CV

About Chengdu Olymvax Biopharmaceuticals, Inc.

Chengdu Olymvax Biopharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available